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Abstract
TIGR/MYOC, a novel 504 amino acids (aa) protein of unknown function, has recently been linked to glaucoma. The
protein is both intra- and extracellular and most known mutations map to its C-terminus, an olfactomedin-like domain. To
investigate the properties of a TIGR/MYOC peptide lacking this important domain, we constructed a replication-deficient
adenovirus with the first 344 aa and over-expressed the truncated protein in primary human trabecular meshwork cells and
perfused human anterior segment cultures. The truncated mutant contains the entire N-terminus plus 98 aa of the
olfactomedin-like domain. We found that the delivered truncated mutant accumulates inside the cell, reduces secretion of
endogenous TIGR/MYOC and induces an increase in outflow facility at 48 h post-infection. Based on these findings, we
hypothesize that TIGR/MYOC might have a dual role in trabecular meshwork function. This dual role might be that of an
intracellular modulator of vesicular transport as well as that of a secreted protein involved in extracellular matrix
conformation. Both functions could have a direct effect in maintaining aqueous humor outflow facility. ß 2000 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Glaucoma, a genetically heterogeneous disease, is
the second leading cause of irreversible blindness
worldwide [1]. The disease is, in most cases, the result
of an elevated intraocular pressure (IOP) [2]. This
increase in IOP results from an increased resistance
to aqueous humor out£ow in the trabecular mesh-
work (TM) tissue [3]. Primary open-angle glaucoma
(POAG), the most common form of the disease, af-
fects 1^2% of the US population over 40 years of age
[1]. Recently, a candidate gene has been linked to
juvenile-onset primary open angle glaucoma
(POAG), an autosomal dominant form of glaucoma
with onset before the age of 30 [4^7]. To a lesser
extent, mutations in this gene have also been linked
to families carrying the adult-onset form of the dis-
ease and to some unrelated POAG patients [4,5,7].
The linked gene, trabecular meshwork inducible glu-
cocorticoid response protein (TIGR) was originally
discovered as a gene product speci¢cally induced in
the human TM cells by prolonged dexamethasone
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treatment [8]. It was later reported to be present in
the ciliary body [9] and in the connecting cilium of
the photoreceptor cells where it received the name of
myocilin (MYOC) [10].
The TIGR/MYOC gene is localized to chromo-
some 1q23^25 [4], has three exons and encodes a
protein of 504 amino acids (aa) [9,11]. The amino-
terminal domain of this protein contains two initia-
tion sites, a signal peptide cleavable at position 32, a
leucine zipper-like motif (residues 117^166), and ex-
hibits a 25% homology with the heavy chain of my-
osin [9,11]. The carboxyl-terminal domain is 40% ho-
mologous to olfactomedin, a major component of
the extracellular matrix (ECM) of the olfactory neu-
roepithelium [12]. To date, most mutations linked to
glaucoma are missense mutations and have been
mapped to the third exon of the TIGR/MYOC
gene, the region encoding olfactomedin-like domain
[5,6,13^15]. A predominant mutation, the
Gln368STOP resulting in an N-terminus domain
truncated protein, has been associated with adult-on-
set glaucoma in familial, three sporadic and one nor-
mal healthy individual [4]. Interestingly, a family car-
rying a missense homozygous autosomal dominant
mutation (K423E) does not manifest glaucoma [16].
Those studies suggested that the disease might be
heterozygous-speci¢c and perhaps in£uenced by al-
terations in protein^protein interaction [16].
TIGR/MYOC resolves as a doublet 55 kDa pro-
teins on SDS^PAGE and has been shown to be both
intracellular and secreted to the media [11]. A third,
potentially glycosylated form of the protein has also
been described by the same authors [11]. However,
the function of TIGR/MYOC remains largely un-
known. It has been suggested that accumulation of
this protein in the ECM might contribute to the ob-
struction of the out£ow pathway and result in an
elevation of IOP [11,17].
The TM consists of di¡erent cell types arranged in
a characteristic architecture. The inner uveal and cor-
neoscleral regions, closer to the anterior chamber,
are comprised of cells lining collagen-elastin beams.
The deeper juxtacanalicular region is composed of
cells that lay relatively free underneath the
Schlemm’s canal (SC). And, the cells of the inner
wall of the SC, tightly connected to each other and
forming what looks like a barrier to the aqueous
humor £uid entering the canal. The whole TM tissue
is embedded in a continuously changing extracellular
material. In the intact tissue, these cells do not di-
vide, but are metabolically very active [18]. Under
appropriate conditions, TM cells can be propagated
in culture for a limited number of passages (7^9).
Our approach to investigate the function of TIGR/
MYOC involves the use of recombinant adenoviral
vectors, known to express their genes in non-prolif-
erating cells. To examine TIGR/MYOC contribution
to the regulation and/or maintenance of IOP, we
transferred the protein to perfused human anterior
segment cultures from post-mortem donors [19]. Pre-
viously, we have shown that after intracameral injec-
tion, adenoviral vectors are able to transfer a report-
er gene to all TM cell types in human organ cultures
[20] and living rabbits [21]. We further showed that a
single dose of 107 reporter adenovirus plaque form-
ing units (pfu) does not have a deleterious e¡ect on
out£ow facility while retaining positive gene transfer
[20].
To elucidate the role of the TIGR/MYOC N-ter-
minal domain, we constructed a replication-de¢cient
adenovirus with the ¢rst 344 aa and over-expressed
this truncated protein in human primary TM cells
(HTM) and perfused organ cultures. The truncated
protein contains the whole N-terminal domain plus
an additional 98 aa of the olfactomedin-like, carbox-
yl-terminal domain. Our results document that the
TIGR/MYOC form lacking the olfactomedin-like
domain cannot be transported out of the cell, sug-
gesting this domain plays a role in intracellular traf-
¢cking. In addition, we demonstrate that over-ex-
pression of the N-terminal domain results in an
increase of out£ow facility in perfused anterior seg-
ments from post-mortem human eyes.
2. Materials and methods
2.1. Cell culture
Cultures of HTM cells were obtained using the
blunt dissection technique in conjunction with
ECM digestion [22]. Non-glaucomatous, donor eye
tissue was obtained from the National Disease Re-
search Interchange (NDRI), a non-pro¢t organiza-
tion engaged in the procurement and distribution
of human tissues for biomedical research in the
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USA. Cell lines used in these experiments originated
from three di¡erent donors, ages 19 (HTM42,
HTM27) and stillborn infant (HTM29), and they
were used at passages 4^6. The 293 cell line (adeno-
virus E1A-transformed human embryonic kidney
cells) and the human umbilical vascular endothelial
cells (HUVEC) were obtained from the American
Type Culture Collection (ATCC). HTM and 293
cells were maintained in Improved Minimal Essential
Medium (IMEM) (Bio£uids, Rockville, MD, USA)
supplemented with 10% fetal bovine serum (Gibco
BRL, Rockville, MD, USA) and 50 Wg/ml gentami-
cin (Gibco BRL); HUVEC were maintained follow-
ing recommendation of the provider (ATCC).
2.2. Perfused anterior segment organ culture
Post-mortem normal human eyes were obtained
from NDRI and every pair had the signed consent
of the patient and followed the Tenets of the Decla-
ration of Helsinki. The ages of the donors were be-
tween 74 and 96 years and none of them had been
diagnosed with glaucoma. Organ cultures were pre-
pared within 30^40 h of death as described previ-
ously [19,20]. Brie£y, eyes were dissected at the equa-
tor and their lens, iris and vitreous were removed.
The anterior segments were then clamped to a two
cannula, modi¢ed petri dish and perfused at constant
£ow with Dulbecco’s modi¢ed Eagle’s medium con-
taining 100 U/ml penicillin, 100 Wg/ml streptomycin,
170 Wg/ml gentamicin and 250 Wg/ml amphotericin B.
Organ cultures were maintained at 37‡C, 5% CO2 for
a maximum of 5 days. Flow rates of 3^4.5 Wl per min
were maintained constant in each case with a Har-
vard microinfusion pump. IOPs were continuously
monitored with a pressure transducer connected to
the dish’s second cannula and recorded with an au-
tomated computerized system. Viability of the TM
after perfusion was assessed in representative pairs
by either morphological examination (light and/or
electron microscopy) or biochemical parameters
(quality of their RNA or protein).
2.3. Construction of recombinant adenoviruses
AdhTIG1, the replication-de¢cient recombinant
adenovirus encoding the truncated form of TIGR/
MYOC, was obtained by overlap recombination.
The TIGR/MYOC cDNA originated from the
HTM27 cell line induced with 1U1037 M dexame-
thasone for 10 days. Total RNA was reverse-tran-
scribed with oligodT and ampli¢ed using forward
5P-GCGAAAGCTTTCCAGAGGAAGCCT-3P (42^
62 nucleotides (nt) TIGR/MYOC cDNA) and re-
verse 5P-CCAGGATCCCTGAGCATCTCCTT-3P
(1645^1623 nt TIGR/MYOC cDNA) primers.
TIGR cDNA nt numbering is according to the tran-
scription initiation site in Adam et al. [13]. The for-
ward primer contains three extra nt in its 5P and a
change from a G to A in TIGR/MYOC nt 43 in
order to create a £anked HindIII restriction site.
The reverse primer contains a change from a G to
a T (reverse strand) in TIGR/MYOC nt 1639 in or-
der to create a £anked BamHI. The ampli¢ed insert
was cloned into the pCR 2.1 vector (Invitrogen, San
Diego, CA, USA) (pJH5). The pJH5 plasmid insert
was ampli¢ed with the same primers, digested with
HindIII/BamHI and subcloned into the shuttle vector
pGEM-CMV [23] under the transcriptional control
of the cytomegalovirus (CMV) promoter and SV40
polyadenylation (poly(A)) signals. This second am-
pli¢cation generated a stop codon in the cDNA
and encoded a truncated protein of 344 aa (see Sec-
tion 3). The pGEM-CMV vector [23] contains Ad5
sequences 1^194 (inverted terminal repeat) that
would provide the adenovirus left terminus and
Ad5 sequences 3328^5781 for overlap recombination.
The resulting shuttle plasmid, pPG301, was linear-
ized with AgeI and co-transfected with an Ad5 arm
into 293 cells by calcium phosphate/DNA co-precip-
itation. The viral arm was obtained from Ad.PacLgal
[23] by digestion with XbaI/ClaI and isolation of the
27 kb fragment by L-agarase I (New England Bio-
labs, Beverly, MA, USA). Vectors pGEM-CMV,
Ad.PacLgal and ‘empty vector’ (identical to Ad.PacL
gal but the transgene is absent) were generously pro-
vided by Dr. Sam George (Duke University Medical
Center, Durham, NC, USA). DNA precipitates were
exposed to the cells for 12 h, washed exhaustively
and allowed to recombine for 2 weeks. After recom-
bination, harvested cells were lysed and their super-
natant assayed for plaque puri¢cation by agar over-
lay [21].
Recombinant viruses were obtained from well-sep-
arated plaques, ampli¢ed and tested for the presence
of TIGR/MYOC cDNA by the polymerase chain
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reaction (PCR) of the puri¢ed viral DNA. The
TIGR/MYOC insert of one positive clone was fully
sequenced in both orientations. High-titer viral
stocks were obtained by propagation in 293 cells
and puri¢cation by CsCl density centrifugation as
described [20,21]. Puri¢ed viruses were titered by
plaque assay in 293 cells [21] and stored in aliquots
at 370‡C. Absence of contaminant wild type viruses
was tested in each stock by PCR ampli¢cation with
E1A primers 5P-TCGAAGAGGTACTGGCTGAT-
3P and 5P-TGACAAGACCTGCAACCGTG-3P, gen-
erously provided by Dr. Jean Bennett (Schei Eye In-
stitute).
Plasmid pMC2, containing the full coding TIGR/
MYOC cDNA, was originated from a non-dexame-
thasone-induced HTM27 cell line on its ¢fth passage.
Total RNA was reverse-transcribed with oligodT
and ampli¢ed using forward 5P-GCGAAAGCTTTC-
CAGAGGAAGCCT-3P (42^62 nt TIGR/MYOC
cDNA) and reverse 5P-CCAGGATCCCTGAGCA-
TCTCCTT-3P (1645^1623 nt TIGR/MYOC cDNA)
primers. Ampli¢cation product was cloned into the
pCR 2.1 vector (Invitrogen).
2.4. Cell-free synthesis of TIGR/MYOC
Recombinant plasmids, containing the T7 pro-
moter and either the described truncated (pPG301)
or full coding (pMC2) TIGR/MYOC cDNAs, were
transcribed and translated in vitro using a TNT T7
Quick Reticulocyte Lysate system kit (Promega,
Madison, WI, USA). Plasmid DNA (0.5 Wg) and
20 WCi of [35S]methionine (NEN, Boston, MA,
USA) were added to the reticulocyte mix on a ¢nal
reaction volume of 25 Wl and incubated at 30‡C for
90 min. To determine co-translational and initial
post-translational modi¢cations, the reticulocyte re-
action was supplemented with 2.0 Wl of canine pan-
creatic microsomal membranes (Promega). For pro-
tease protection, reaction mixtures were brought to
10 mM Ca2Cl and chilled on ice. Aliquots were in-
cubated with 0.1 mg/ml proteinase K (Gibco BRL)
in presence or absence of 1% Triton X-100 for 30
min on ice. Proteolysis was stopped by the addition
of 1 mM phenyl-methylsulfonyl £uoride (PMSF) and
incubation for an additional 10 min. Endoglycosi-
dase H (Endo H) (New England Biolabs) was used
to determine the glycosylation of translation prod-
ucts. Endo H digestion of in vitro labeled TIGR/
MYOC followed the protocol of the manufacturer.
Reactions were stopped by the addition of Laemmli
bu¡er and its products analyzed by 10% SDS^PAGE
and autoradiography.
2.5. Delivery of recombinant adenoviruses to cells and
organ cultures
For the tissue culture, cells seeded on 6-well dishes
were allowed to reach 80^90% con£uence and in-
fected with AdhTIG1 at a multiplicity of infection
of 50^100 pfu/cell for 1 h in serum-free medium.
Viral absorption continued for 18 h in the presence
of 10% serum. After viral exposure, media were re-
placed with complete IMEM and cultures evaluated
48 h post-infection. Control dishes were treated with
Ad.PacLgal and empty vector at the same pfu/ml or
with the same volume of viral vehicle under identical
conditions.
For the organ cultures, paired eyes were perfused
with standard medium for a minimum period of 24 h
to allow stabilization of baseline out£ow facility. Per-
fusion pumps were then stopped and pressure al-
lowed to drop to 95 mm Hg before eyes were in-
jected with 20 Wl of the AdhTIG1 viral solution
(107 pfu) using a 50 Wl Hamilton syringe and a
1 cm beveled 30 G disposable needle. Contralateral
eyes were injected with 20 Wl of either vehicle or 107
pfu of control viruses (Ad.PacLgal and empty vec-
tor). The injection was performed by inserting the
needle through the cornea, pushing the plunger in
very slowly and allowing a few moments before re-
moving it. The dish was then rocked gently front to
back and side to side 2^3 times to mix the sample
inside the chamber. Pumps were restarted and perfu-
sion continued for approximately 48 h post-injection.
2.6. Out£ow facility measurements of the human
organ cultures
Pressure values were obtained from readings re-
corded just before injection (baseline) and every 6 h
between 24 and 48 h post-infection. Out£ow facility
(C), also de¢ned as the inverse of the resistance (R)
(C = 1/R), was calculated as the rate of the £ow (F)
divided by the IOP, P (Goldmann’s equation, C =
F/P). It is measured in Wl/min/mm Hg. Only eyes
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with a stable baseline for over 20 h were used for
these experiments. Data from each experiment are
calculated as percent change of facility from the
baseline and results from each eye are combined
into a group and expressed as the mean þ S.E.M.
Experimental e¡ects are statistically obtained by
comparing the percent change in out£ow facility of
the experimental eyes with the percent change in fa-
cility of the controls by the paired, two-tailed t-test.
2.7. Western blot analysis
Proteins were extracted by boiling samples for
10 min in 1ULaemmli bu¡er, followed by centrifu-
gation at 16 000Ug and storage of supernatants at
320‡C. For HTM cultures, media and cells from
each 35 mm well were collected separately. After re-
moving the medium, the cell monolayer from each
well was washed twice with phosphate-bu¡ered saline
(PBS; Gibco BRL) followed by the addition of
1ULaemmli bu¡er to a concentration of 3U107
cells/ml. The medium from each corresponding well
was centrifuged at 140Ug for 7 min followed by a
second centrifugation at 41 000Ug for 30 min to re-
move cellular debris. Cleared medium containing se-
creted cell products was then concentrated 20U on a
Centricon C-10 ¢lter (Amicom-Millipore, Bedford,
MA, USA) followed by bu¡er exchange to 0.01 M
Tris^HCl pH 7.4. Harvesting of the cells under non-
reducing conditions was done using the Laemmli
bu¡er without dithiothreitol (DTT). For organ cul-
ture, isolated perfused human TM tissue from each
anterior segment was washed with PBS at 0‡C,
brie£y centrifuged at 180Ug at 4‡C and resuspended
in 20 Wl of ice-cold bu¡er (0.1 M NaCl, 0.01 M Tris^
HCl pH 7.4, 0.001 M EDTA, 100 Wg/ml PMSF).
Prior to protein extraction, chromosomal DNA was
sheared by passage through a 23 G needle. E¥uents
from 48 h perfused time (post-infection) were col-
lected from the reservoirs of control and infected
perfused chambers, centrifuged at 16 000Ug for
15 min and applied to a NAP-10 column (Pharma-
cia, Piscataway, NJ, USA) equilibrated with 10 mM
Tris^HCl pH 7.4. After the addition of 100 Wg/ml of
PMSF plus one volume of 2ULaemmli bu¡er, pro-
teins were extracted as indicated above.
Protein extracts were separated by 10% SDS^
PAGE and electro-transferred to a PVDF membrane
(Bio-Rad, Hercules, CA, USA). After blocking with
5% non-fat dry milk in PBS^0.2% Tween 20 (Sigma,
St. Louis, MO, USA) for 2^4 h, membranes were
incubated overnight at 4‡C with rabbit polyclonal
TIGR/MYOC antibodies raised in this laboratory
[24] (1:2000 dilution). Immunoreactive bands were
visualized by chemiluminescence (ECL, Amersham,
Piscataway, NJ, USA) following treatment with
anti-rabbit IgG secondary antibodies conjugated to
horseradish peroxidase (Pierce, Rockford, IL, USA)
(1:6000 dilution). For detection and proper quanti-
tative analysis of TIGR/MYOC in HTM cultures,
1/10 of each of the total cell extract from infected
and control samples were run in parallel with 1/10
volume of their corresponding supernatants. For the
organ cultures, 1/7 of infected and control tissue pro-
teins were run in parallel with aliquots corresponding
to 1/100 of their own e¥uents. TIGR/MYOC bands
were scanned with an UC1260-Umax scanner and
analyzed using the NIH Image 1.61 software. Calcu-
lations to compare intra- and extracellular TIGR/
MYOC in the control and infected HTM primary
cultures were then performed using the total amount
of TIGR/MYOC in the cell extract plus that in its
corresponding supernatant. Normalization for poten-
tial di¡erences in cell numbers and control for cell
lysing during the infection and extraction procedure
was accomplished by measuring the amount of L-
tubulin in blots of the same samples ran in parallel
wells incubated with an anti-rat brain L-tubulin
monoclonal antibody (clone TUB2.1, Sigma).
2.8. Immunocytochemistry
For double labeling of TIGR/MYOC protein and
microtubules, cells in cover slips were permeabilized
with MT-stabilization bu¡er (80 mM Pipes, 1 mM
MgCl2, 2 mM EGTA, pH 6.9) containing 0.02% Tri-
ton X-100 (4U for 1 min each, 37‡C), ¢xed with
methanol (320‡C, 5 min) and air-dried. Cells were
washed, incubated with an anti-rat brain L-tubulin
monoclonal antibody (clone TUB2.1, Sigma) for 1 h
at room temperature (RT), washed and incubated
(1 h, RT) with TRITC-conjugated goat anti-mouse
(1/250) (Sigma). Subsequently, cells were washed and
exposed to the TIGR/MYOC antibody [24] (1:250)
for 4 h, followed by the addition of a FITC-labeled
goat anti-rabbit (Biosource, Camarillo, CA, USA)
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(1:1000) for 1 h. All solutions were made in PBS as
were the washes performed in between all incubation
steps (3U, 5 min each). Cover slips were mounted
with 10 Wl Fluoromount G (Southern Biotechnology
Associates, Birmingham, AL, USA) and analyzed
with a Zeiss Axioplan £uorescence microscope.
3. Results
In this study, we used the recombinant virus Adh-
TIG1 encoding the N-terminal domain of the TIGR/
MYOC protein and constructed as described in Sec-
tion 2. Fig. 1, upper panel, shows a diagram of the
viral DNA while the lower panel shows that of the
viral encoded truncated protein. When compared to
TIGR/MYOC cDNA sequence (GenBank accession
number AF001620; [13] for nt position numbering),
the recombinant viral insert DNA presents one nt
change (A to G at nt position 105) and a deletion
of 35 nt (nt positions 1048^1082). At the protein
level, the single nt change results in the aa conversion
Ser10 to Gly. These mutations were generated in the
process of subcloning the original pJH5 into the ex-
pression vector pPG301 and were not present in the
gene of the original cell line nor generated by the
dexamethasone treatment. The nt deletion yields a
change of three aa before creating a stop codon at
aa 345 (see Fig. 1). The protein encoded by this
recombinant cDNA contains the whole N-terminal
domain with the signal peptide plus 98 aa from the
olfactomedin-like domain. Computer comparison of
the AdhTIG1 insert TIGR/MYOC cDNA translated
sequence with the sequence of the putative protein
linked to the POAG stop mutation showed a di¡er-
ence in length at their carboxyl end of 23 aa (Fig. 1).
To explore the presence of a functional signal pep-
tide and the potential in£uence of the construct’s
Ser10Gly mutation in its cleavage, we used empirical
and experimental approaches. For the empirical, we
analyzed the sequence with SignalP V2.0 (http://
www.cbs.dtu.dk/services/SignalP-2.0/), a program
that uses neural networks and hidden Markov mod-
els to predict the presence and location of signal
peptide cleavage sites [25,26]. We found that the
presence of a signal peptide in the non-mutated se-
quence (Ser at position 10) was predicted with a
probability of 0.974 and C, S and Y score values
of 33, 33 and 28, respectively. For the mutated se-
quence (Gly at position 10), the same algorithms
Fig. 1. Schematic representation of the recombinant adenovirus AdhTIG1 DNA and its encoded protein. AdhTIG1 DNA containing
the TIGR/MYOC cDNA insert under the transcriptional control of the CMV promoter and SV40 poly(A) signals. The TIGR/MYOC
ATG initiation codon and the premature TGA stop codon of the construct are indicated. Arrow-heads point to approximate locations
of TIGR/MYOC mutations before the TGA. Lower bar is a representation of the AdhTIG1-encoded protein containing the N-termi-
nal domain (hatched) and 98 aa of the olfactomedin-like domain (solid black). A sequence comparison of the olfactomedin domain of
the proteins encoded by AdhTIG1, POAG Glu368STOP mutation and full-length TIGR/MYOC cDNA are written underneath the
bar. TIGR/MYOC cDNA nt numbering is according to Adam et al. [13].
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predicted a probability of 0.975 and C, S and Y score
values identical to those obtained on the non-mu-
tated one. For the experimental approach, we per-
formed in vitro transcription/translation reactions
with the truncated and full-length containing plas-
mids in the presence and absence of microsomal
membranes (Fig. 2A). In the absence of microsomal
membranes, a single major band was obtained for
both truncated and full-length cDNAs (Fig. 2A,
lanes 1 and 5). The molecular weight (MW) of the
major bands corresponded to the expected size of the
truncated and full-length proteins. In the presence of
microsomes, both single bands were cleaved in a sim-
ilar manner into two smaller MW products (Fig. 2A,
lanes 2 and 6). The cleaved products were resistant to
proteinase K treatment (Fig. 2A, lanes 3 and 7) and
Fig. 2. Cell-free synthesis assay of truncated TIGR/MYOC and full-length TIGR/MYOC. Recombinant plasmids (0.5 Wg) containing
the truncated (pPG301) (left) and full-length coding TIGR/MYOC cDNA (pMC2) (right) were translated using a TNT T7 rabbit re-
ticulocyte lysate in a 25 Wl reaction containing 20 WCi of 35S for 90 min. A: Reactions were conducted in the absence (lanes 1 and 5)
or presence (lanes 2 and 6) of 2 Wl of canine microsomal membranes. For translocational controls, aliquots from the microsomal reac-
tion were treated with 0.1 mg/ml of proteinase K in the absence (3) or presence (+) of 1% Triton X-100. The proteinase K lanes (3
and 7) show protection of the cleaved proteins. The degradation of the bands in the presence of Triton X-100 (lanes 4 and 8) re£ects
the translocation of the protein to the membranes. B: For glycosylation assays of the processed products, aliquots of the in vitro reac-
tions were treated with Endo H according to manufacturer’s directions. The reduction of size observed for the mutant and wild type
TIGR/MYOC after Endo H treatment re£ects the removal of glycosyl side chains added to the nascent protein. Aliquots (3 Wl) from
each reaction were run in a 10% SDS^PAGE gel and analyzed by autoradiography.
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sensitive to the enzyme in the presence of detergent
(Fig. 2A, lanes 4 and 8). To identify the nature of the
cleaved products, the reactions were further treated
with Endo H, an enzyme that cleaves the N-acetyl
glucosamine residues of glycosyl side chains (Fig.
2B). This treatment produced a shift in electropho-
retic mobility of the higher MW bands into the lower
MW ones (Fig. 2B, lanes 4 and 8), indicating that
both the truncated and wild type form of TIGR/
MYOC are glycosylated at the predicted site [11].
Since N-linked glycosylation occurs only within in-
tact microsomes, these results show that both trun-
cated and full-length TIGR/MYOC forms are trans-
located to the endoplasmic reticulum (ER) for
processing. All bands from the non-cleaved and
cleaved products were recognized by immunoprecipi-
tation with the TIGR/MYOC antibody (data not
shown).
Northern blot analysis using the full-length TIGR/
MYOC cDNA as a probe revealed an over-expres-
sion of the recombinant mRNA in infected organ
cultures and primary HTM cells (data not shown).
Western blot analysis using the TIGR/MYOC anti-
body [24] showed that protein extracts from infected
TM in organ cultures and primary cells contained, in
addition to the endogenous protein (TIGR/MYOC-
e) at 55 kDa, a doublet protein band around 43 kDa
(TIGR/MYOC-r) (Fig. 3). This doublet band was
not present in the controls and had the expected
size for the truncated TIGR/MYOC encoded by
the recombinant adenovirus (Fig. 3). The few extra
bands seen in the infected culture are currently be-
lieved to be degradation products. Infection of HU-
VEC with AdhTIG1 resulted in the expression of the
same recombinant protein (not shown).
Neither the e¥uents from perfused human anterior
segment cultures nor the supernatants from the pri-
mary HTM cells contained the TIGR/MYOC-r, in-
dicating that the truncated form of the protein is not
secreted into the medium (Fig. 3). In contrast, the
same blots clearly showed the presence of the full,
endogenous TIGR/MYOC in all extracellular sam-
ples, infected and non-infected (Fig. 3). Interestingly,
the amount of endogenous TIGR/MYOC in the
extracellular fraction appeared to be diminished in
the AdhTIG1-infected cultures (Fig. 3). The lack of
resolution of the endogenous protein as a doublet
band in the supernatants of the infected cells is due
to the presence of concentrated serum that a¡ects
band mobility. Moreover, normal TIGR/MYOC se-
Fig. 3. Immunoblotting analysis of TIGR/MYOC in cell extracts and supernatants of control and AdhTIG1-infected samples. Left:
perfused anterior segments from a post-mortem donor were injected in one eye with 107 pfu AdhTIG1 while the contralateral was in-
jected with vehicle. Equivalent ratios of tissue extract (T) to e¥uent (E) from infected and control eyes at 48 h post-infection. Right:
primary HTM cultured cells infected with 50^100 pfu/cell of AdhTIG1, Ad.PacLgal or control vehicle. Equivalent volumes (1/10) of
cell extracts (cells) and of their corresponding supernatants (spnt) from infected and control samples at 48 h post-infection. All sam-
ples were run on SDS^PAGE gels and transferred to a PVDF membrane. Speci¢c proteins were detected with a TIGR/MYOC poly-
clonal antibody and visualized by chemiluminescence. Immunoreactive bands corresponding to TIGR/MYOC mutants are not present
in the supernatants while the intensity of the wild type endogenous bands is reduced.
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cretion was not reduced in cultures infected with a
recombinant adenovirus carrying a reporter gene.
This result indicates that the e¡ect observed with
AdhTIG1 was most likely due to the over-expression
of the truncated TIGR/MYOC protein and not to
the adenovirus itself (empty virus) or to the presence
of an excess delivered protein in the cell (Ad.PacL
gal). Re-probing of the membranes with a monoclo-
nal L-tubulin antibody failed to detect L-tubulin in
any of the extracellular fractions, indicating their
lack of intracellular material.
To estimate the percentage of the secreted form of
TIGR/MYOC, we used Western blots containing
equivalent volumes of cell extracts and supernatants
and analyzed their immunoreactive TIGR/MYOC
bands by densitometry. For each sample, the total
amount of TIGR/MYOC was calculated by adding
the densitometry values of each cell extract plus that
of its own supernatant. Calculations are based on six
independent experiments using three di¡erent HTM
cell lines from three non-related donors. In the con-
trol cultures, the content of extracellular TIGR/
MYOC-e was calculated to be approximately 79%
of the total amount of TIGR/MYOC (Fig. 3). For
the AdhTIG1-infected cells, the amount of TIGR/
MYOC-e in the extracellular medium was only 49%
(Fig. 3), indicating a reduction in secretion of about
30%. Moreover, in these experiments, the amount of
intracellular TIGR/MYOC-e increased proportional-
ly, suggesting that the observed reduction in secre-
tion was not due to protein degradation. In contrast,
the ratio of extra- to intracellular TIGR/MYOC of
HTM cells infected with Ad.PacLgal, empty vector
or virus vehicle was the same as that of the control
(Ad.PacLgal shown in Fig. 3). Similar results were
obtained when the perfused organ culture e¥uent
was compared with the extract from the intact tissue
(Fig. 3). However, because the e¥uent of the anterior
segment cultures might not be exclusively a TM
extracellular medium, calculations of the percentage
of TIGR/MYOC in this system were not performed.
Removal of the reducing agent from the loading
bu¡er changed the electrophoretic mobility of both
endogenous and recombinant TIGR/MYOC bands
to a higher MW, indicating their ability to form
dimers and multimers (Fig. 4).
Immunocytochemical staining of HTM cells in-
fected with AdhTIG1 showed that the truncated
TIGR/MYOC form localized primarily to the peri-
nuclear region with a somewhat punctate pattern ex-
tending toward, but not reaching, the cell membrane
(Fig. 5b,c). The lack of TIGR/MYOC staining in the
cell membrane demonstrates that the absence of
truncated protein in the media observed in Western
blots is actually due to impairment in secretion
rather than to loss of the mutant in the cell mem-
brane fraction. No positive staining was obtained in
any of the uninfected non-dexamethasone-induced
HTM cell lines, including those with positive West-
ern blots (Fig. 5a), indicating that the amount of
endogenous TIGR/MYOC in normal conditions is
not high enough to be detected by immuno£uores-
cence. At the light microscopy level, over-expression
of the exogenous truncated TIGR/MYOC did not
seem to in£uence the HTM cell phenotype.
To investigate the physiological e¡ect of the over-
expression of the truncated TIGR/MYOC protein,
we performed perfusion of post-mortem human an-
terior segments and measured changes in IOP. Ex-
Fig. 4. Electrophoretic mobility shift of truncated and endoge-
nous TIGR/MYOC under non-reducing conditions. Primary
HTM cultures were infected for 48 h with 100 pfu/cell of virus
AdhTIG1 expressing the truncated TIGR/MYOC. Proteins
were extracted from infected wells with 1USDS Laemmli bu¡er
in the presence (+) or absence (3) of reducing agent (100 mM
DTT). Equivalent volumes of cell extracts were loaded on
SDS^PAGE gels, transferred to PDVF membranes and ana-
lyzed by immunoblotting. Speci¢c protein forms were detected
with TIGR/MYOC polyclonal antibody and visualized by
chemiluminescence.
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periments were performed with paired eyes. The
average out£ow facility at baseline was 0.22 þ 0.04
(n = 24). Fig. 6 shows the percent change in out£ow
facility of 12 pairs from which one of the eyes was
injected with 107 pfu of AdhTIG1 while the contra-
lateral eye was injected with vehicle. Viability of the
TM after perfusion was assessed in representative
pairs by morphological examination (four out of
12) and biochemical evaluation (two out of 12). In
two of the pairs, the contralateral eye was injected
with 107 pfu of the reporter adenovirus Ad.PacLgal
and in one pair the contralateral eye was injected
Fig. 6. E¡ect of a single dose of the recombinant adenovirus
AdhTIG1 on the facility of out£ow of post-mortem human an-
terior segments perfused at constant £ow (n = 12). Out£ow fa-
cility was calculated as the rate of £ow divided by the recorded
reading of the IOP. Percent changes are calculated from base-
line values obtained before injections. Adenovirus expressing
the truncated TIGR/MYOC, at a single dose of 107 pfu (b),
showed an increase of 27 þ 10% of facility at 36 h after infec-
tion compared to one of 7 þ 7% in the vehicle-injected, contra-
lateral eyes (a) (P = 0.024). At 48 h post-infection, the increase
in out£ow facility of the infected eyes reached a value of
31 þ 10% compared to one of 6 þ 8% in the vehicle-injected,
contralateral controls (P = 0.014).
Fig. 5. Intracellular localization of truncated TIGR/MYOC by
immuno£uorescence. Primary HTM cells were infected with 50^
100 pfu/cell of virus AdhTIG1 expressing the TIGR/MYOC
truncated protein. At 48 h post-infection, cells were ¢xed, per-
meabilized and processed for immuno£uorescence. Cells were
double-stained for L-tubulin and TIGR/MYOC with speci¢c
antibodies using TRITC- (L-tubulin) and FITC- (TIGR/
MYOC) conjugated secondary antibodies (Section 2). a and b:
Visualized with the overlay of FITC green and TRITC red
channels. c: Visualized with the FITC channel. a, Uninfected
control; b and c, same frame of AdhTIG1-infected cells. The
TIGR/MYOC protein detected is the truncated form encoded
by AdhTIG1. The endogenous TIGR/MYOC is not detected in
the absence of dexamethasone induction. Original magni¢ca-
tion: a, b, c: 400U ; frame c was slightly enlarged by the
Adobe Photoshop software.
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with empty vector. Anterior segments injected with
AdhTIG1 exhibited a 31 þ 10% increase in out£ow
facility (C) compared to the baseline C0 (n = 12)
(Fig. 6) at 48 h post-treatment. This increase began
24 h after injection and reached a peak at 42 h. The
facility of out£ow of the contralateral eyes demon-
strated a good stability with a 6 þ 8% change at 48 h.
The two-tailed t-test performed between treated and
untreated eyes had the ¢rst signi¢cant P value
(P = 0.024) at 36 h and reached P = 0.014 at 48 h.
4. Discussion
Mutations in the C-terminal, conserved sequence
of the olfactomedin-like domain of the TIGR/
MYOC protein have been genetically linked to indi-
viduals with glaucoma [5,6,13]. These mutations have
been mapped throughout the domain without, to
date, the identi¢cation of a particular hot spot. In
the present study, we made use of a recombinant,
replication-de¢cient adenovirus to investigate the ef-
fects of over-expression of an N-terminal truncated
mutant in TM cells and intact tissue. Our goal by
using this recombinant was to provide a new insight
into the function of a TIGR/MYOC peptide lacking
the olfactomedin domain.
The adenoviral vector AdhTIG1 was able to deliv-
er high concentrations of the truncated mutant pro-
tein to HTM cultured cells and perfused TMs from
post-mortem donors’ eyes. In both systems, the re-
combinant protein is not secreted and accumulates in
large amounts inside the TM cells while the endoge-
nous full-length TIGR/MYOC is detected in cell ex-
tracts as well as in the media. In addition, the 43
kDa recombinant protein is also able to form multi-
mers, indicating that the N-terminal fraction might
be responsible for the initial oligomerization of the
protein, possibly through the leucine zipper motif.
By empirical sequence analysis, it has been re-
ported [9,11] that a hydrophobic region at the
TIGR/MYOC amino-terminal carries a signal pep-
tide [25] with a potential cleavage at aa 32
(VGAsRT). This signal peptide was determined us-
ing the neural network algorithm [25] that discrimi-
nates between signal peptides and signal anchors. In
this study, we show that the in vitro synthesis of full-
length and truncated TIGR/MYOC in the absence of
microsomes resulted in the presence of one major
band, indicating that only one of the two predicted
translation initiation sites is preferentially used. In
the presence of microsomes, we observed two pro-
teinase K resistant bands. When treated with Endo
H, the higher MW bands of truncated and full-length
shifted their electrophoretic mobility to the lower
ones. This resistance to proteinase K plus their sen-
sitivity to Endo H are a clear indication that both
forms of the protein are processed inside the micro-
somal vesicles, an environment similar to the lumen
of the ER. Moreover, the mutation present in the
signal sequence of our recombinant (Ser10Gly) did
not a¡ect the cleavage of the signal peptide as pre-
dicted by the neural network algorithm [25,26].
Based on their migrating distance and the Endo H
sensitivity, the two processed bands appear to corre-
spond to a signal peptide proteolytic cleavage and its
glycosylated form. Altogether, these results demon-
strate that a functional signal peptide targets the
truncated and full-length forms of TIGR/MYOC to
the ER.
Signal peptides control the entry of virtually all
proteins into the secretory pathway explaining why
TIGR/MYOC appears in the extracellular compart-
ment [11]. However, in contrast to the full-length
TIGR/MYOC, this recombinant lacking the olfacto-
medin domain is not secreted. It seems as if the
TIGR/MYOC secretory signal is not su⁄cient for
its exocytosis and suggests that the mechanism of
its secretion might not depend exclusively on the sig-
nal peptide.
Another interesting ¢nding was that elevated con-
centrations of the truncated protein inside the cells
appear to in£uence the secretion of endogenous, full-
length TIGR/MYOC. In fact, the percentage of en-
dogenous TIGR/MYOC in the extracellular fraction
was greatly reduced in infected samples while the
total amount of endogenous protein was not a¡ected
nor degraded. These results together with the appar-
ent punctated vesicular pattern observed could sug-
gest a potential role of TIGR/MYOC in cell secre-
tion.
Vesicles are an essential part of intracellular traf-
¢cking and consist of multiple protein complexes
that are involved in its generation, membrane target-
ing, bi-directional transport and exocytosis of their
cargo proteins [27,28]. Whether TIGR/MYOC could
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be an intrinsic part of the vesicles, one cargo protein
or both cannot be determined by these experiments.
On one hand, the fact that the truncated form ap-
pears to localize to vesicles without being secreted
would suggest that the protein might be part of the
vesicle complex. On the other, the fact that 80% of
the full-length TIGR/MYOC-e is secreted into the
media would argue for its presence in the vesicles
as a cargo protein. Interestingly, it has been shown
recently that some cargo proteins interact with their
vesicle components and that this interaction is im-
portant for proper vesicle function [28]. The full
function of TIGR/MYOC might then be determined
by protein^protein interactions involving the olfacto-
medin-like domain. In this regard, it is interesting to
note that proteins of the olfactomedin family are
able to form oligomers through essential cysteine res-
idues which are conserved in TIGR/MYOC [6,29].
Furthermore, it is known that the ‘priming complex’
protein (SNARES) [28] required to generate vesicles
relies on the formation of oligomers. Perhaps the
olfactomedin-like domain is important for those pro-
tein^protein interactions between TIGR/MYOC (as
a cargo protein) and the vesicle priming complex, as
have been shown for other cargo proteins [30].
Therefore, proper vesicle function in the HTM might
depend on the presence of a full-length TIGR/
MYOC. It is tempting to speculate that our results
showing a 30% reduction in secretion of endogenous
TIGR/MYOC in HTM cells which over-express the
truncated form could indicate a disruption in vesicle
function.
Alternatively, the TIGR/MYOC localization ob-
served and its inability to exit the cell could be an
indication that the mutated protein is retained in the
ER because of defective folding. To this e¡ect, it is
interesting to note that a mutant of K1-anti-trypsin, a
secreted glycoprotein linked to emphysema and liver
disease, hinders its own secretion [31]. Some believe
that the pathogenesis of this protein could result
from a major change in its conformational properties
[32]. Recently, it has been shown that K1-anti-trypsin
mutated proteins are associated with a complete in-
tracellular transport block and remain Endo H sen-
sitive, an indication that the block is between ER
and Golgi complex, where proteins become Endo
H resistant [33].
Injection of a single dose of AdhTIG1 produced a
reduction in IOP (increase in out£ow facility) in the
perfused anterior segments of post-mortem human
eyes (Fig. 6). Experimental changes in out£ow fa-
cility can be produced by many di¡erent mecha-
nisms, among them, changes in the amount and/or
composition of the ECM [34]. In our experiments,
reduction of IOP was associated with a reduction
of wild type TIGR/MYOC in the e¥uent of the in-
fected organ cultures. It is possible that the inhibition
in secretion caused by the mutant form is not only
speci¢c for wild type TIGR/MYOC but also a¡ects
other proteins involved in ECM turnover. Poten-
tially, changes in extracellular TIGR/MYOC and/or
other ECM components could contribute to alter
ECM con¢guration and thus enhance the £ow path-
way within the trabecular tissue.
The molecular mechanisms as to how TIGR/
MYOC is involved in the development of glaucoma
are not yet clear. Some discrepancies exist. The pres-
ence of its mutated form (either missense or non-
sense) in conjunction with the wild type (heterozy-
gous individuals) is associated with the disease while
the only case of a reported homozygous mutation is
not associated with glaucoma [16]. In addition, wild
type TIGR/MYOC is strongly induced by dexameth-
asone, causing some authors to hypothesize that
extracellular TIGR/MYOC accumulation could itself
produce secondary glucocorticoid glaucoma [17]. We
believe that protein^protein interactions are a key
factor in the proper execution of TIGR/MYOC pro-
tein function. In a disease causing heterozygous, the
wild type/mutant strand complex could be retained
inside the cell. This might sequester other needed
extracellular proteins bound to the olfactomedin do-
main of its wild type strand. In a non-disease causing
homozygous, the mutant/mutant strand complex
would remain intracellular but would not retain the
same proteins because of their inability to bind to its
defective olfactomedin domain. Our results of an in-
creased out£ow facility after over-expressing the mu-
tant protein might concur with the idea that homo-
zygous for TIGR/MYOC mutants are not
deleterious. It is possible that, when present at higher
than physiological concentrations (over-expression),
the mutant/mutant protein could even be bene¢cial,
perhaps by retarding secretion of unwanted proteins.
Then, the state of homo- or heterozygosity in TIGR/
MYOC mutations as well as mutations at di¡erent
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sites would result in di¡erent folding con¢gurations
and could in£uence not only the development but
also the severity of the disease. Experiments to test
these di¡erent hypotheses with TIGR/MYOC are in
progress.
In summary, we have observed that the recombi-
nant truncated TIGR/MYOC does not get degraded
and, in contrast to the endogenous form, is unable to
exit the cell. Accumulation of this mutated form in-
side the cell reduces secretion of the endogenous
form and induces a decrease in IOP in perfused hu-
man anterior segment cultures. Our results point to a
potential dual e¡ect on vesicular transport and ECM
composition and give new insight into the functional
correlation of this novel protein with the develop-
ment of glaucoma.
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